The results of solitary pancreas (SP) transplantation have traditionally lagged behind those of simultaneous pancreas-kidney (SPK) transplantation. This is one of the chief factors that has limited the wide-scale application of SP transplantation in nonuremic type I diabetic patients. The purpose of this study is to report our present experience with SP transplantation and compare it to a prior experience. Twenty-three SP trans plants (14 PAK, 4 PTA, and 5 PASPK) performed since January 1997 were compared to 56 SP transplants (53 PAK, 1 PTA, and 2 PASPK) performed before 1994. Between 1993 and 1997, SP transplants were not performed because of high morbidity in the early experience. Early SP transplants were performed using bladder drainage of exocrine secretions, and enteric drainage without a Roux-en-Y was used in the recent series. In the early era, immunosuppressive therapy included cyclosporine (CsA), azathioprine (AZA), corti costeroids, and in half of the patients, ALG or OKT3. Recent SP transplants received tacrolimus (TAC), mycophenolate mofetil (MMF), corticosteroids, and induction with either anti-thymocyte globulin (n = 9), OKT3 (n= 1), daclizumab (n = 5), or basiliximab (n = 8). The 1-year Kaplan-Meier patient survival was 85% in the early era and 100% in the recent group of patients (p = 0.08). In the previous era, four patients suffered significant decrement in renal function, necessitating dialysis or kidney transplantation following pancreas transplantation. All patients transplanted since 1997 maintain near prepancreas transplant levels of renal function [mean pretransplant serum creatinine (Cr) 1.3 ± 0.3 mg/dl vs. mean current Cr 1.4 ± 0.4 mg/ dl, p = NS]. The 1-year Kaplan-Meier graft survival (insulin independence) of recent SP transplants was 87%, whereas for prior SP transplants it was 19% (p = 0.0001). The rate of acute pancreas rejection was significantly different between the two groups. Of early SP transplants, 76% experienced at least one rejec tion episode within the first year. In contrast, 35% of recent SP transplants suffered acute rejection during the same time period (p = 0.04). Current experience with SP transplantation demonstrates improved graft survival and reduced rejection rates with the use of newer immunosuppressive agents.
INTRODUCTION
One of the principal factors that has restricted the acceptance of solitary pancreas (SP) transplantation as a treatment option for nonuremic type I insulin-dependent diabetics is the fact that long-term graft survival of SP transplants has been poor and inferior to that of com bined kidney-pancreas transplantation. Instead, the ma jority of pancreas transplants performed in the US be tween 1980 and 1997 have been done in combination with a kidney transplant from the same donor and have been reserved for uremic diabetics (22) . The reason for poorer graft survival in SP transplantation compared to simultaneous pancreas-kidney (SPK) transplantation is thought to be due to several factors.
In the setting of SPK transplantation, pancreas rejec tion is commonly coincident with renal allograft rejec tion and rarely occurs in isolation. Therefore, traditional means of monitoring for allograft rejection by serum creatinine and renal allograft biopsy are reliable methods for assessing the immunologic stability of the pancreas graft. However, in the setting of SP transplantation, ei ther the kidney is from a prior donor or the recipient's native kidneys remain functioning and monitoring for pancreas rejection depends on assessment of the pan creas graft alone. Before 1995, standard maintenance immunosuppression for transplantation consisted of a cyclosporine (CsA) and azathioprine (AZA)-based regi men and was associated with an incidence of acute re jection of 70-75%, despite the addition of routine poly clonal antibody induction therapy to immunosuppressive protocols by most pancreas transplant centers. Because of the high incidence of acute rejection and the fact that a sensitive and specific serum indicator of rejection was not available, and pancreas allograft biopsies were not routinely performed, most patients suffered graft loss from unremitting immunologic rejection. As a result of uniformly poor graft survival rates, potential recipients were generally not offered this surgical therapeutic op tion.
The availability of tacrolimus (TAC) and mycophenolate mofetil (MMF) in 1995 and their proven efficacy in kidney (6, 12, 13, 16, 19) , heart (9) , and liver transplan tation (4) led to utilization of these agents in immuno suppressive protocols in pancreas transplantation. Sev eral studies have recently reported reduced rejection rates and excellent short-term graft function in TACtreated SPK and SP recipients (2, 6, 7, 20) and in MMFtreated SPK patients (15) . At our institution beginning in 1997, we combined TAC and MMF in an intensified immunosuppressive regimen in SP transplantation in an attempt to improve graft survival rates. This report ana lyzes our results with this immunosuppressive protocol and compares it with our previous experience with SP transplantation in the CsA-AZA era.
PATIENTS AND METHODS

Study Population
Between (14) .
Demographics of the two groups of patients are shown in Table 1 . The two groups were significantly different in several respects. Whereas patients in the re cent group were older and had diabetes for a longer time, their renal function was better at the time of pan creas transplantation. The cold ischemia time was signif icantly longer in recent experience primarily due to im proved cold preservation in UW solution.
Exocrine Drainage Procedures
The method for managing pancreatic exocrine secre tions evolved over time at our institution. All prior SP transplants were done with bladder drainage (BD) using a variety of techniques including segmental pancreas transplantation with pancreatic duct cystostomy (n = 11, 6 with a concomitant surgically created arteriovenous fistula), duodenal button cystostomy (n = 38, 9 with con comitant splenic transplant), and whole pancreaticoduo denal allograft with duodenocystostomy (n = 7). In the recent era, 100% were enteric drained (ED) using a sideto-side duodenojejunostomy without Roux-en-Y diver sion.
HLA Matching
No effort was made to HLA match pancreas to recipi ent prior to transplantation. The mean HLA mismatch in both groups was 4.3 ± 1.2 antigens. Despite prior trans plants and transfusions, the majority of patients (91%) in both groups had low panel reactive antibody (PRA) titers at the time of transplantation; high PRA status is not considered an exclusion criteria for SP transplanta tion at our center.
Immunosuppression
In the early era, 52% of transplants received induc tion immunotherapy with Minnesota anti-lymphocyte globulin (MALG, 20 mg/kg/day IV x 7-14 days), 11% received OKT3 (Orthoclone OKT3, Ortho Biotech, Inc., Raritan, NJ; 5 mg/day IV x 7-14 days), and 37% did not receive antibody induction therapy. All but one pa tient were treated with CsA (Sandimmune, Sandoz Phar maceuticals, East Hanover, NJ). CsA levels were ad justed to achieve whole blood levels between 200 and 250 ng/ml. Eighty-eight percent of patients received azathioprine (150 mg per day) and 12% of patients received Cytoxan (1 mg/kg/day). A standard corticosteroid induc tion and maintenance protocol was equivalent in both groups; weaning from steroid therapy was not attempted in either group of patients.
In the current era, a quadruple therapy simultaneous induction protocol was used in all patients. Induction antibody therapy consisted of anti-thymocyte globulin (n = 9) (ATGAM®, Upjohn, Kalamazoo, MI; 15 mg/kg/ day IV x 7 days), Thymoglobulin® (n = 2) (Sangstat, Menlo Park, CA; 1.5 mg/kg/day IV x 7 days), OKT3 in = 1), basiliximab (n = 8) (Simulect®, Novartis, East Han over, NJ; 20 mg/day IV on days 0 and 4), or daclizumab 
RESULTS
Patient Survival
Fifty-six solitary pancreas transplants performed in has abated and baseline renal function is maintained ( Fig. 2) . Furthermore, we have not observed acute rejec tion in a prior renal allograft following SP transplanta tion.
Pancreas Graft Survival
The 2-year Kaplan-Meier graft survival (insulin inde pendence) of prior SP transplants was 14%. Poor shortand long-term graft survival in this group of patients in our early experience was a reason for abandoning this procedure at our institution from 1993 to 1997. Since we adopted TAC-MMF-based immunosuppression in SP transplants, a substantially improved 2-year graft sur vival rate (87%, p = 0.0001) has been achieved (Fig. 3) .
The causes of graft loss in the early group were: 29 (52%) acute and chronic rejection, 10 (18%) thrombosis, 6 (11%) expired with functioning graft, and 7 (13%) infection or pancreatitis. There were two graft losses in the recent group; one due to an enteric leak and the other acute rejection that went unrecognized and progressed to a necrotizing vasculitis and thrombosis. Thus, immu nologic graft losses account for the majority of the dif ference in graft survival between the two eras.
Acute Rejection Episodes
Of SP transplants performed in the early era, 42 (76%) experienced at least one rejection episode within the first year postoperatively. In contrast, 8 (33%) recent SP transplants suffered acute rejection (p = 0.04). Figure   4 shows the Kaplan-Meier rates for time to first rejection for both groups. There was also more recurrent rejection in the prior group (41% vs. 0%, p<0.0\) (Fig. 5 ). In the early era, 9 of 33 (27%) first rejections were treated with bolus corticosteroids alone and 20 (60%) received combination bolus corticosteroids and a course of ALG or OKT3; in four pancreatectomy pathologic specimens acute rejection was diagnosed and no therapy was given.
On the other hand, eight acute rejection episodes in re cent SP transplants within the first year and one thereaf ter were treated with OKT3 in addition to steroids.
In agnosed and treated before onset of glucose intolerance in all but two patients.
Complications
The rates of major surgical and infectious complica tions were similar in both groups (1-year Kaplan-Meier rates: 1982-1993 76.8% vs. 1997-present 56.6%, p = NS), though there were fewer patients with more than one major complication per patient within the first year in the recent era than in the early period. That is, in the prior era, 64% of patients experienced more than one major complication, whereas only 18% of recent SP transplants suffered more than one complication (p < 0.01).
The rates of opportunistic infections, including her pes, CMV, fungal, and Pneumocystis infections, were compared between the two groups and were not found A likely significant factor in the success of recent SP transplants in this study is the utilization of percutaneous allograft biopsy and histologic diagnosis of rejection.
Although we cannot analyze these factors in isolation, several other recent studies have acknowledged the im portance of an accurate diagnosis of rejection by graft biopsy (11, 21) . Particularly given the absence of a sensi tive and specific serologic marker for pancreas rejection, histology is essential in differentiating the various causes of graft dysfunction. In pancreas rejection, lymphocytic infiltrates initially involve the exocrine por tion of the gland, manifesting first clinically as exocrine dysfunction and enzyme elevation. Endocrine dysfunc tion or hyperglycemia is understood as a late-stage find ing. Of course, it is recognized that hyperamylasemia is a nonspecific sign and has many causes. Therefore, it appears useful to use exocrine dysfunction rather than hyperglycemia as a primary indication to perform a bi opsy. Thus, by diagnosing and treating rejection early and aggressively, one can anticipate better preservation of islet function and better graft survival. Furthermore, without a biopsy many episodes of hyperamylasemia might be considered to be due to nonimmunologically mediated benign pancreatitis. In the past, an inability to differentiate immunologically mediated injury from a benign cause that does not require antirejection therapy may have led to cases of overtreatment or undertreatment. By specifically identifying the etiology of graft dysfunction, appropriate therapy is assured and the dev astating consequences of empiric overimmunosuppression avoided.
Reperfusion pancreatitis, primary nonfunction, and graft thrombosis were rare in the recent series of SP transplants. Preservation with UW solution and evolu tion of surgical techniques have undoubtedly aided in near elimination of these events (18) . A direct retrospec tive comparison of the effects of preservation in UW solution on pancreas transplantation cannot be carried out because the routine use of UW solution in our pan creas transplant program was initiated at approximately the same time CsA was incorporated into clinical prac tice in 1986. However, numerous animal and human studies have demonstrated a reduction in cellular swell ing and maintained microcirculation, ultimately reduc ing the risks of postoperative pancreatitis and thrombo sis (1, 17, 23, 24) . Whether the change in exocrine drainage technique from bladder drainage used in prior transplants to enteric drainage used in recent SP trans plants in this series could possibly contribute to the dif ferences in graft survival observed cannot be determined from this study. However, because the International Pan creas Transplant Registry (IPTR) and several single cen ter studies have not detected significant differences in graft survival and rejection rates when comparing BD vs. ED SPK transplants (3, 10, 22) , we feel it is doubtful that a change to ED in SP transplants would have a sig nificant beneficial effect. In fact, analysis of the IPTR data for isolated pancreas transplants demonstrates bet ter long-term graft survival results in BD allografts (22) . This has been interpreted as indicating that bladder drainage is particularly useful in SP transplants because it gives one the ability to noninvasively monitor exo crine dysfunction and rejection by determining urinary amylase levels in a setting where kidney function is not available as a marker. However, the sensitivity and spec ificity of urinary amylase monitoring is approximately the same as serum amylase, and this test is cumbersome for patients; therefore, we have not found it useful. Fur thermore, in our recent series of SP transplants, we have achieved a graft survival rate equivalent to that of a con current group of SPK transplants while using ED and without monitoring urinary amylase levels.
The immunosuppressive regimen used in the recent series of SP transplants deserves mention. This is the first report of the use of anti-CD25 monoclonal antibod ies in pancreas transplantation. The use of these mono clonal antibodies for induction in combination with MMF and TAC in this small group of patients appears to be safe, nondiabetogenic, and efficacious. A subset analysis of antibody induction therapy was done and did not yield any differences between polyclonal antibodies and anti-IL-2R monoclonal antibodies in rejection rates or graft survival, although the numbers of patients are quite small. Two controlled comparative studies have previously analyzed the efficacy of TAC in SP trans plantation (2, 8) . Both studies demonstrated improved graft survival in TAC-treated SP transplants when com pared to CsA-treated historical controls. In both studies, however, a subset of TAC-treated patients received MMF therapy. Therefore, in these studies and in ours it is not possible to determine which individual immuno suppressive agent, or perhaps the combination of both, was associated with improved graft survival. Nonethe less, it appears that a TAC/MMF-based regimen is effec tive and safe in SP transplantation.
Lastly, MMF is initially dosed at 3 g/day orally or 2 g/day IV until patients are taking oral fluids and then switched to 3 g/day orally. The same regimen is used for SPK patients who are also receiving Neoral or TAC. In stable patients, doses are reduced for clinical indica tions including diarrhea, significant gastrointestinal symptomatology, leukopenia, viremia, significant sepsis, weight loss of unknown etiology, or malignancy. Other wise, patients are maintained on the maximal tolerated dose throughout their postoperative course. Dosing ad justments appear similar between SP and SPK transplant recipients. However, by 1 year after transplantation, only 40% of SPK patients were still receiving full dose MMF and in 10% MMF was discontinued (15) .
In summary, excellent short-term pancreas graft sur vival can be achieved in high-risk solitary pancreas transplant recipients with TAC-MMF-based immuno suppression. The incidence of biopsy-proven rejection is reduced, but remains significant. This fact highlights the importance of accurate detection of rejection by biopsy of the graft and early, aggressive antirejection therapy to permit optimal preservation of endocrine function.
